tiprankstipranks
Medicenna Therapeutics Corp (MDNA)
NASDAQ:MDNA

Medicenna Therapeutics Corp (MDNA) Stock Price & Analysis

154 Followers

MDNA FAQ

What was Medicenna Therapeutics Corp’s price range in the past 12 months?
Currently, no data Available
What is Medicenna Therapeutics Corp’s market cap?
Currently, no data Available
When is Medicenna Therapeutics Corp’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Medicenna Therapeutics Corp’s earnings last quarter?
Currently, no data Available
Is Medicenna Therapeutics Corp overvalued?
According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
    Does Medicenna Therapeutics Corp pay dividends?
    Medicenna Therapeutics Corp does not currently pay dividends.
    What is Medicenna Therapeutics Corp’s EPS estimate?
    Medicenna Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Medicenna Therapeutics Corp have?
    Currently, no data Available
    What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?
    Currently, no hedge funds are holding shares in MDNA
    ---

    Company Description

    Medicenna Therapeutics Corp

    Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R) which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The IL4-ECs have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.
    ---

    MDNA Stock 12 Months Forecast

    Average Price Target

    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
    Similar Stocks
    Company
    Price & Change
    Follow
    Medicenna Therapeutics Corp
    Resverlogix
    Reliq Health Technologies
    BriaCell Therapeutics
    Sirona Biochem

    Best Analysts Covering MDNA

    1 Year
    Swayampakula RamakanthH.C. Wainwright
    1 Year Success Rate
    0/15 ratings generated profit
    0%
    1 Year Average Return
    -60.72%
    reiterated a buy rating 8 months ago
    Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -60.72% per trade.
    Popular Stocks
    ---
    What's Included in PREMIUM?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis